

**File. No. 29/Misc/03/2018-DC (389)**  
**Government of India**  
**Directorate General of Health Services**  
**Central Drugs Standard Control Organisation**  
**(Medical Devices Division)**

FDA Bhawan, Kotla Road,  
New Delhi-110002  
Dated: 11.09.2018

**Public Notice**

**Subject: - Constitution of "Central Expert Committee" and "State Level Committee" to determine the quantum of compensation in respect of faulty ASR Hip Implants manufactured by M/s DePuy International Limited, U.K. (now M/s Johnson & Johnson Pvt. Ltd) implanted in India-regarding.**

Ministry of Health and Family Welfare, Govt. of India had constituted a high powered Expert Committee to examine issues related to the faulty ASR Hip Implants manufactured by M/s. DePuy International Limited, UK, (now M/s. Johnson & Johnson Pvt. Ltd) and imported by M/s. DePuy Medical Pvt. Ltd, Mumbai, (now Johnson & Johnson Pvt. Ltd.). The committee has submitted the report to the Ministry. The recommendations of the committee have been accepted with certain modifications by the Ministry of Health & Family Welfare, Govt. of India and the report has already been uploaded on the CDSCO website.

The committee has recommended, amongst other things, the constitution of central expert committee and state level committee for determining the exact quantum of compensation.

Accordingly the Central Government has now constituted a Central Expert Committee under the chairmanship of Dr. R. K. Arya, Director, Sports Injury Center, Safdurjung Hospital, Ministry of Health & Family Welfare, Govt. of India, New Delhi to determine the quantum of compensation as admissible under appropriate law and medical management for the affected patients who were implanted faulty ASR Hip implant. The Govt. has also requested the Principal / Health Secretaries of all States/UTs to constitute the State Level Committee to examine the affected patient's details in their respective states.

The affected patients who are implanted faulty ASR Hip Implant and are suffering from disability and other losses may approach either Central Expert Committee or State Level Committee as per their convenience. In case the affected patients intend to approach Central Expert Committee, they may write / mail to Legal cell, CDSCO (HQ), FDA Bhawan, Kotla Road, New Delhi – 110002, Phone Number 011-23216367, Ext 315, Email ID: [legalcell@cdsco.nic.in](mailto:legalcell@cdsco.nic.in)

In case the affected patients intend to approach State Level Committee, they may write to concerned State Drugs Controller who will be the Member Secretary of State Level Committee.

This issues with the approval of Ministry of Health & Family Welfare, Govt. of India.



**(Dr. S. Eswara Reddy)**  
**Drugs Controller General (India)**